source
- Regeneron halts Phase 1/2 uveitis antibody trial over unfavorable risk-benefit profileRegeneron has stopped a Phase 1/2 study of its anti‑inflammatory antibody REGN7041 in non‑infectious uveitis, citing an unfavorable benefit‑risk assessment. The antibody targets CD3 on immune cell…
- Leo Pharma to license Tanabe’s oral drug for rare light-sensitive skin disease, paying up to $435 millionLeo Pharma announced a licensing agreement with Japan's Tanabe Pharma for an oral treatment targeting two genetic skin disorders that cause pain when exposed to sunlight. Under the deal, Leo Pharm…